177Lu-Satoreotide is under clinical development by Ariceum Therapeutics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 177Lu-Satoreotide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
177Lu-Satoreotide overview
177Lu-satoreotide (OPS-201, SOMther) is under development for the treatment of meningiomas, small cell lung cancer. It is administered through intravenous route. The drug candidate is based on theranostic approach. It is a radioligand therapy, next generation somatostatin analog coupled to the strong DOTA chelating agent labeled radio conjugated with a short-life, beta-ray emitting isotope like 90Yttrium with improved receptor binding to sst2.
It was also under development for metastatic breast cancer, neuroendocrine gastroentero pancreatic tumors (GEP-NET), paraganglioma (Glomus Jugulare Tumor) and pheochromocytoma.
Ariceum Therapeutics overview
Ariceum Therapeutics is a biotechnology company that discovers and develops radiopharmaceutical products for the diagnosis and treatment of cancer. The company’s product pipeline includes the SSO110 program against neuroendocrine tumors (NETs) and small cell lung carcinoma (SCLC). It also evaluates SSO120 to diagnose neuroblastoma and other solid tumors. Ariceum’s technology approach to designing and developing targeting molecules coupled with radioactivity to identify and bind structures on the tumor cell surface. The company was funded by Pureos Bioventures, EQT Life Sciences, HealthCap, and other companies. Ariceum is headquartered in Berlin, Germany.
For a complete picture of 177Lu-Satoreotide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
